Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sight Sciences, Inc.

Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences to Host Surgical Glaucoma Investor Symposium on Friday, May 5, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers GLS PEAR SGHT
Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences to Present at the Upcoming Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Announces 1,000th TearCare® Customer Installation
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Results
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Improvements in Signs and Symptoms of Dry Eye Disease From a Single TearCare® Treatment Sustained Through 12 Months
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences to Present at the Upcoming Piper Sandler 34th Annual Healthcare Conference
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Reports Third Quarter 2022 Financial Results
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
From Sight Sciences, Inc.
Via GlobeNewswire
Tickers SGHT
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.